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Abstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the 
treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly   selective 
for DPP  -4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4   inhibitors 
elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gas-
tric inhibitory polypeptide (GIP). This effect results in a glucose-dependent   stimulation of insulin 
secretion and an inhibition of glucagon secretion without an intrinsic risk for   hypoglycemia. In 
comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors 
are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for 
Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in 
doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients 
receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic 
parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy 
for glycemic parameters in various patient populations either in monotherapy or in combination 
with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. 
With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an 
attractive novel DPP-4 inhibitor.
Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, 
saxagliptin
Introduction
The prevalence of type 2 diabetes is increasing dramatically worldwide. Estimations 
by the International Diabetes Federation (IDF) forecast the total number of people with 
diabetes to be 440 million worldwide by the year 2030.1 The increase in type 2 diabetes 
prevalence will inevitably lead to an increase of the complications and comorbidities 
of this disease. Efficacious and safe treatment options for type 2 diabetes are needed 
to prevent hypoglycemia and diabetes-related complications.
The pathophysiology of type 2 diabetes mainly comprises two phenomena: insulin 
resistance and a disturbance of insulin secretion. While insulin resistance is fairly 
  constant in the time course of type 2 diabetes, the disturbance in insulin secretion 
worsens during the course of the disease due to continuously declining islet func-
tion. Decreasing islet function is the driving force for type 2 diabetes disease pro-
gression. This development is aggravated by chronically persisting hyperglycemia, 
elevated plasma concentrations of free fatty acids, cytokines, adipokines and toxic 
metabolic products that are detrimental for islet function and finally lead to a loss of 
beta-cell mass. The glucagon-secreting alpha cells in the islet additionally develop a Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 118
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secretory defect. In nondiabetes people, glucagon secretion 
is   suppressed   during hyperglycemia, but in type 2 diabetes 
subjects   glucagon secretion during hyperglycemic conditions 
does not become suppressed. The relative   hyperglucagonemia 
is possibly causal to the excessive glucose production by the 
liver observed in type 2 diabetes.2–5
The older treatment options for type 2 diabetes are limited 
and do not address the problem of islet-cell   dysfunction. Clas-
sical insulin secretagogues (sulfonylureas and glynides) exclu-
sively act on the beta-cell and stimulate insulin   secretion, but do 
not address the secretion defect of the alpha cells.   Metformin 
and thiazolidinediones have a beneficial influence on insulin 
resistance, but have   important   contraindications. These are 
impaired renal function for   metformin and heart failure for 
thiazolidinediones. The therapy with thiazolidinediones leads to 
an undesired gain in body weight. Alpha-glucosidase inhibitors 
delay the breakdown of complex carbohydrates and therefore 
act mainly on postprandial metabolism. With insulin therapy, 
a relative lack of insulin can be replaced and the endogenous 
secretory insulin deficit can be overcome, but insulin therapy is 
associated with a risk for hypoglycemia and weight gain. The 
increasing loss of islet function characterizing type 2 diabetes 
is not ameliorated by any of the classical treatment option.2–5
In the past few years, incretin-based therapies have 
become available offering promising ways to overcome 
the limitations of the classical treatment options for type 2 
diabetes described above.
The incretin hormones glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic peptide (GIP) are 
secreted after a meal from the intestinal L- and K-cells 
respectively and physiologically stimulate   insulin secretion 
postprandially. They are responsible for the incretin effect 
that described the phenomenon that orally ingested   glucose 
evokes a greater insulin response than an   intravenously 
administered glucose infusion calculated to lead to identical 
serum glucose excursions.6–8
The physiology of GLP-1 and its possible promising role 
as a pharmacological tool for treating type 2 diabetes was first 
described in the late 1990s. In contrast to the   classical insulin-
otropic agents (sulfonylureas and glynides), the   insulinotropic 
action of GLP-1 is strictly glucose dependent. GLP-1 stimu-
lates insulin secretion only   during   hyperglycemia. This effect 
provides the possibility of   glucose normalization without the 
risk of hypoglycemia. In patients with type 2 diabetes with 
hyperglycemia, exogenous   parenteral GLP-1 application 
stimulates insulin secretion and normalizes both fasting and 
postprandial blood glucose. GLP-1 is also able to restore the 
defective first phase of insulin secretion in type 2 diabetes.2
Besides these antihyperglycemic effects, GLP-1 also 
  possesses additional noninsulinotropic physiological actions 
that are attractive for type 2 diabetes treatment: GLP-1 sup-
presses glucagon secretion from the alpha-cells also in a glucose 
dependent manner. Under hyperglycemic conditions, glucagon 
secretion is inhibited, while under hypoglycemia, glucagon 
secretion is even increased. The latter effect also contributes to 
the low hypoglycemia risk with GLP-1 based therapies.2,9
Furthermore, GLP-1 slows gastric emptying and 
  gastrointestinal motility. It also acts as a mediator of satiety in 
the hypothalamus, where it is an important n  eurotransmitter.2,5 
These two actions are responsible for the observation that in 
healthy subjects and type 2 diabetes patients GLP-1   infusions 
lead to decreased caloric intake and consecutively weight 
loss.10,11
GLP-1 has beneficial effects on beta-cell function and 
mass by stimulating beta-cell formation from precursor cells 
and inhibiting beta-cell apoptosis.2,11,12
Dipeptidyl peptidase-4 (DPP-4) is the enzyme that is 
responsible for the degradation of GLP-1 resulting in its short 
biological half-life of only 1–2 minutes. Due to the extremely 
short biological half-life, treatment with native GLP-1 is 
not feasible. In order to use GLP-1 effects as therapeutic 
principle, long-acting GLP-1 receptor agonists have been 
developed as an injectable therapy. The other alternative to 
utilize GLP-1 action is the inhibition of the degrading enzyme 
DPP-4 by orally active DPP-IV inhibitors.2,13
DPP-4 is a ubiquitous enzyme and is found in the 
  endothelium of various organs as well as measurable 
  circulating enzymatic activity in plasma in soluble form. 
Besides GLP-1 many other peptides are substrates of 
DPP-4, but the affinity towards GLP-1 is predominant. 
DPP-4 cleaves and inactivates GLP-1 within a few 
  minutes.14 DPP-4 is also expressed on the cell membrane 
of   activated T-lymphocytes where it was first described as 
CD26 receptor.14 The enzymatic functions and the active 
center of DPP-4 are, however, localized in a distant part 
of the molecule in respect to the CD26 receptor function. 
An influence of DPP-4 inhibitors on i  mmunological CD26 
mediated   functions is therefore not expected and unlikely. 
The broad clinical use of DPP-4   inhibitors has so far not 
revealed serious side effects or adverse events on immuno-
logical regulatory mechanisms.2
DPP-4 inhibition promotes an attractive therapeutic 
principle by increasing plasma concentrations of   endogenous 
GLP-1. While GLP-1 receptor agonists are injectable 
  compounds, DPP-4 inhibitors are orally active.2 DPP-4 
belongs to the enzyme family of endopeptidases. DPP-4 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 119
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inhibitors must therefore have a high selectivity to inhibit 
only DPP-4 and not other DPPs. The DPP-4 inhibitors sita-
gliptin and vildagliptin have already been approved in many 
countries and have been shown to be efficacious and safe due 
to their DPP-4 selectivity.15,16 Saxagliptin, a novel DPP-4 
inhibitor, was developed by AstraZeneca and Brystol-Myers 
Squibb and has just been approved (trade name Onglyza®). 
Further DPP-4 inhibitors such as alogliptin, dutogliptin and 
linagliptin are in development.17,18
Development, synthesis  
and preclinical pharmacology  
of saxagliptin
In the development of DPP-4 inhibitors, a long duration 
of action was a desirable feature. Compounds with a vinyl 
  substitution at the β-position of α-cycloalkyl-substituted gly-
cines and their oxygenated metabolites did not lead to a loss 
of potency, but to a desired increase in duration of action.19,20 
Consecutive exploration of molecules with an hydroxylated 
adamantyl group led to saxagliptin, that is characterized by 
a high in vitro and in vivo potency, good oral bioavailabil-
ity (F = 75%), good duration of action (t 1/2 = 2.1 hours) 
and no CYP3A4   inhibition.20–23 Saxagliptin interacts with 
DPP-4 at the Ser630 residue in the active center of DPP-4. 
The   formation of the covalent complex of saxagliptin and 
DPP-4 is reversible, with a dissociation constant (koff) of 5.5 ± 
0.4 × 10−5 s−1 and an equilibrium constant Ki* (as koff/kon) 
for the formation of the covalent intermediate of 0.35 nM. 
This value is similar to the value obtained from steady-state 
inhibition studies of 0.6 nM.21,24,25
Saxagliptin has a very high selectivity for DPP-4 and its in 
vitro potency shows a 400- and 75-fold higher potency versus 
DPP-4 than for DPP-8 or DPP-9, respectively. It also dem-
onstrates a more than 4000-fold greater potency for DPP-4 
in comparison to a number of other proteases. Saxagliptin 
possesses a dissociation constant for inhibitor binding (Ki) 
of 1.3 ± 0.3 nM for inhibiting DPP-4, making it 10- and 14-
fold more potent than vildagliptin (13 ± 3 nM) and sitagliptin 
(18 ± 2 nM), respectively.26
In vivo saxagliptin has an IC50 value for DPP-4 inhibition 
of 30 nM and ED50 values at 0.5 and 6 hours were attained 
with saxagliptin at 0.1 and 0.5 µmol/kg, respectively, dem-
onstrating a good activity over time and long duration. A 
significant rise of endogenous GLP-1 was observed after 
an oral glucose challenge in healthy rats with a saxagliptin 
dose of 3 µmol/kg and no inhibition of T-cell activity was 
detected.20,21
The in vivo DPP-4 inhibitory activity in Sprague-  Dawley 
rats was 87%. The Ki value was 0.6 ± 0.06 nM, the ED50 
  values at 0.5, 2, 4 and 6 hours post-administration were 
0.12 ± 0.04, 0.2 ± 0.07, 0.3 ± 0.10 and 0.5 ± 0.15 µmol/
kg,   respectively. In a diabetes, insulin-resistant rat model, 
  saxagliptin (0.3 to 3 µmol/kg po) improved glucose   clearance 
by 28%–61%   relative to controls at 2 hours after glucose 
  challenge. Saxagliptin was also effective at raising insulin 
levels and increasing glucose clearance in ob/ob mice at 1, 
3 or 10 µmol/kg po.24
In man, the IC50 for DPP-4 inhibition by saxagliptin is 30 
nM, the ED50 0.5 and 6 hours after a single dose are 0.1 and 
0.5 µmol/kg, respectively. Therefore, saxagliptin has suf-
ficient activity over time for once daily dosing. Saxagliptin 
is metabolized in humans forming an active metabolite. The 
active metabolite BMS-510849 is 2-fold less potent than 
saxagliptin. The endogenous GLP-1 concentrations rise 
1.5- to 3.0-fold after oral administration of saxagliptin.21,27 
Pharmacokinetic and pharmacodynamic properties of 
  saxagliptin were investigated in healthy subjects at doses up 
to 400 mg daily and in type 2 diabetes patients in doses from 
2.5 mg to 50 mg od. The maximally DPP-4 inhibiting effect 
of saxagliptin was observed at a single dose of 150 mg. Per-
centages of DPP-4 inhibition 24 hours post-dose for 2.5 mg 
and 400 mg saxagliptin were 50% and 79% of the predose 
activity, respectively. Doses of 400 mg od saxagliptin for 
2 weeks were safe and well tolerated.21,28 So far, no specific 
drug–drug interactions were detected for saxagliptin and 
other commonly used medications.29–32
Clinical studies with saxagliptin
Phase 1 studies showed a dose dependent DPP-4 inhibition in 
a dose range from 2.5 to 100 mg saxagliptin given once daily. 
In a large phase 2 study in drug-naive patients (n = 350) with 
inadequately controlled type 2 diabetes saxagliptin was given 
in doses of 2.5, 5, 10, 20 or 40 mg/day po for 12 weeks or 
100 mg/day po for 6 weeks. The baseline HbA1c ranged from 
6.8%–9.7%. In the placebo group, 20% of patients achieved 
HbA1c levels of 7.0%, compared with 50%, 47%, 41%, 50%, 
53% and 66% of patients in the saxagliptin groups, respec-
tively.   Fasting plasma glucose and post-challenge glucose after 
a liquid meal were also dose dependently and significantly 
improved by saxagliptin.21,28,33 A subsequent phase 2B/phase 3 
study investigated saxagliptin as add-on to metformin. Patients 
on a stable dose of   metformin (1500–2550 mg/day) and a base-
line HbA1c 7.0%–10.0% were enrolled.   Saxagliptin was tested 
against placebo at doses of 2.5, 5 or 10 mg od administered 
as add-on to metformin. A total of 743 patients participated Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 120
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in this 24-week trial. Saxagliptin led to a decrease in HbA1c 
compared to placebo of −0.73%, −0.83% and −0.71% from 
a baseline of 8.0 ± 0.9% for the 2.5, 5 or 10 mg dose after 24 
weeks, respectively (P  0.0001). The fasting plasma glucose 
also significantly decreased by −16, −24 and −21 mg/dL from 
a baseline of 176 ± 46 mg/dL (P  0.0001). In oral glucose 
tolerance tests, saxagliptin significantly improved glycemic 
excursions and reduced the glucose and glucagon AUCs 
while increasing the AUCs for insulin and C-peptide. The 
therapy with saxagliptin was well tolerated and the incidence 
of hypoglycemic events was on placebo level. The treatment 
with saxagliptin was weight neutral (body weight change of 
−1.5, −0.9, −0.5, and −1.0 kg for 2.5, 5, and 10 mg saxagliptin 
and placebo, respectively).34
The study program leading to the approval of saxagliptin 
was extensive. Figure 1 shows the phase 3 program of the 
clinical studies and the number of patient’s involved.34–38
A dose-range study in drug naïve type 2 diabetic 
patients with an HbA1c of 6.8%–9.7% (mean 7.9%) at 
baseline were treated with saxagliptin in a dose range from 
2.5 mg to 40 mg once daily. The treatment with saxagliptin 
led to a dose-dependent placebo subtracted reduction in 
HbA1c by 0.45%–0.63%. The fasting- and postprandial 
plasma   glucose concentrations were also lowered dose-
dependently by saxagliptin. The drug did not cause hypo-
glycemia, was well tolerated and was weight neutral as in 
other studies.36,39
An initial combination therapy with saxagliptin plus 
  metformin versus saxagliptin or metformin monotherapy 
lasting 24 weeks demonstrated that saxagliptin 5 mg plus 
  metformin and saxagliptin 10 mg plus metformin   demonstrated 
  statistically significant decreases in   glycemic parameters. The 
aim of this study was to evaluate the   efficacy and safety of an 
initial combination treatment with   saxagliptin plus metformin 
and compare it to a saxagliptin- or metformin monotherapy in 
treatment-naïve patients with type 2 diabetes and inadequate 
glycemic control. A total of 1306 patients were enrolled in 
this 24-week study. At the end of the trial, the proportion of 
patients reaching an HbA1c goal 7% was 60.3% and 59.7% 
for saxagliptin 5 mg plus   metformin and saxagliptin 10 mg 
plus   metformin,   respectively (all P  0.0001 vs   monotherapy). 
The   incidence of adverse events was   comparable in all groups 
and the overall rate of   hypoglycemic episodes was very low 
on placebo level.38
As add-on therapy in patients treated with a   sulfonylurea, 
saxagliptin, when added to a submaximal dose of   glyburide, 
improved glycemic parameters significantly and was   superior 
to up titrating the sulfonylurea. In this study, a total of 
768 patients were randomized to receive 2.5 mg or 5 mg in 
combination with glyburide 7.5 mg or glyburide 10 mg as 
  monotherapy for 24 weeks. At the end of the study, 92% of 
patients on   glyburide monotherapy were up titrated to a total 
glyburide dose of 15 mg/day, corresponding to the maximal 
dose allowed   according to the study protocol. Saxagliptin at 
the doses of 2.5 mg and 5 mg od provided statistically signifi-
cant adjusted mean decreases of HbA1c from baseline to week 
24 vs up titrated glyburide of −0.54%, −0.64% vs +0.08%, 
respectively (both P  0.0001). Other glycemic parameters 
(fasting plasma glucose, postprandial glucose, proportion 
of patients reaching an HbA1c goal 7%) were significantly 
better in the groups receiving saxagliptin. Reported hypogly-
cemic events were not statistically significantly different for 
saxagliptin 2.5 mg (13.3%) and 5 mg (14.6%) vs up titrated 
glyburide (10.1%) and the incidence of adverse events was 
similar in all groups.37
The efficacy and safety of saxagliptin were also   investigated 
in a study using saxagliptin as an add on to a pre-existing 
therapy with glitazones in type 2 diabetic patients with a base-
line HbA1c of 7.0%–10.5%. A total of 565 patients receiving 
stable glitazone monotherapy (  pioglitazone 30 mg or 45 mg 
or rosiglitazone 4 mg or 8 mg od) were treated with either 2.5 
mg or 5 mg saxagliptin or placebo as add-on for 24 weeks. 
Both doses of saxagliptin (2.5 mg and 5 mg) as add-on to a 
  glitazone led to statistically significant adjusted mean decreases 
in HbA1c vs placebo (−0.66% and −0.94% for saxagliptin 
2.5 mg and 5 mg vs −0.30% for placebo).   Fasting plasma 
glucose, postprandial glucose and the proportion of patients 
reaching an HbA1c goal 7% were significantly improved in 
the saxagliptin treated patients. Saxagliptin was generally well 
tolerated; adverse event occurrence and reported hypoglycemic 
events were similar across all groups.40
A study assessing the efficacy of 5 mg saxagliptin daily 
used different insulin secretion parameters after 12 weeks as 
efficacy measures in 156 patients not well controlled with diet 
and exercise (HbA1c between 6.0% and 8.0%).21,28,33
A study in patients with impaired renal function (  creatinine 
clearance 50 mL/min) is still ongoing and investigating the 
efficacy and safety of 2.5 mg saxagliptin given od.21,28,33
A study in 18 patients with hepatic impairment (Child–
Pugh Score A–C) compared the pharmacokinetics of 10 mg 
saxagliptin to a healthy control group. A higher   elevation of 
AUC values after saxagliptin (10%–77% higher) was observed 
in the patients with hepatic   impairment.   Correspondingly, the 
AUC values for the metabolite were 7%–33% lower, depending 
on the severity of hepatic   impairment. These results indicate 
a reduced capacity to metabolize the drug with increasing Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 121
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Table 1 Monotherapy studies with saxagliptin
Saxagliptin (mg) Placebo Saxagliptin (mg) Placebo
QAM QAM QAM QPM
Dose 2.5 5 10 – 2.5 5 2.5/5 5 –
n = 100 103 95 92 67 69 69 70 68
Basal mean HbAIC (%) 7.91 7.98 7.85 7.88 8.04 7.93 8.02 7.88 7.79
Notes: For HbAIC changes, see Figure 2. 
Abbreviations: QAM, every morning; QPM, every afternoon.
hepatic dysfunction. Saxagliptin, however, was well tolerated 
in subjects with mild, moderate or severe hepatic impair-
ment.21,41
Adverse effects  
and contraindications
In clinical studies, DPP-4 inhibitors are generally well 
  tolerated and fullness, nausea, or other   gastrointestinal symp-
toms related to retarded gastric emptying are rare. Nasophar-
yngitis and urinary tract infections were reported in a small 
  number of patients treated with DPP-4   inhibitors. DPP-4, also 
known as CD26, is found as a membrane protein expressed 
in many different tissues, including   lymphocytes, and in 
a   circulating soluble form; DPP-4   inhibitors also   prolong 
the action of a number of growth   factors,   neuropeptides, 
cytokines, chemokines, and   various   hormones other than 
GLP-1 and gastric inhibitory   polypeptide (GIP). Potential 
side effects therefore include neurogenic   inflammation and 
allergic reactions, which have not been reported in a signifi-
cant number so far.
Saxagliptin in doses up to 100 mg od was tested in   
type 2 diabetes patients and doses up to 400 mg were tested 
in healthy subjects. These doses did not cause specific 
adverse reactions and tolerability was good.21,28,33 Besides 
that, data from longer studies investigating the adverse 
events and safety of saxagliptin are available. In the clinical 
phase 3 program, saxagliptin at doses from 2.5 mg to 10 mg 
od were well tolerated without a significant rise in specific 
adverse reactions compared to placebo. The hypoglycemia 
  incidence was also not increased compared to placebo.21,28,33–40 
A study in formerly drug-naïve type 2 diabetes patients using 
doses of up to 40 mg saxagliptin once daily did not reveal 
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Figure 1 Overview of the clinical study program of saxagliptin leading to approval.45
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a higher incidence of specific adverse events compared to 
the placebo group.39 Possible drug–drug interactions with 
saxagliptin were also examined extensively and did not give 
a signal for drug-drug interactions between saxagliptin and 
common medications.21,29–32 In patients with renal or hepatic 
impairment, additional data have to be obtained to be able 
to evaluate the safety and efficacy of saxagliptin in these 
patient groups. One study in patients with renal impairment 
is still ongoing. In hepatic organ dysfunction, dose reductions 
to lower doses seem to be feasible without additional side 
effects. Saxagliptin was well tolerated in a small study such 
patients receiving a single saxagliptin dose.41
Discussion and perspectives
DPP-4 inhibitors have been introduced into type 2   diabetes 
therapy in 2006 with sitagliptin as first substance,16   followed 
by vildagliptin15 and now saxagliptin in 2009. The DPP-4 
  nhibitors are the first substances having a glucose-  dependent 
dual action on alpha- and beta-cell function   stimulating 
insulin secretion and suppressing   glucagon secretion under 
  hyperglycemic conditions. This dual action leads to an 
improved time course of islet   hormone secretion after a 
meal and in hyperglycemia. The glucose-dependent action 
results in a hypoglycemia risk that is comparable to placebo 
treatment. On the other hand,   hormonal counter-regulation in 
hypoglycemia is not impaired, but actually improved.42 Animal 
studies and in vitro data from isolated human islets suggest 
that DPP-4 inhibitors increase beta-cell function and mass. 
These findings may support the   hypothesis that DPP-4 inhibi-
tors as well as a therapy with GLP-1 analogs have a beneficial 
effect on disease progression of type 2   diabetes.17,18 Clinical 
studies with saxagliptin have   demonstrated very   satisfactory 
data on the   improvement of glycemic parameters together 
with a good safety profile and good tolerability over a time 
range up to 24 weeks in clinical studies in a large cohort of 
patients.21,28,33–39,41,43 (see Tables 1 and 2, Figure 2). In com-
parison to other sitagliptin and vildagliptin, saxagliptin shows 
a similar   efficacy and safety profile in monotherapy as well 
as in the initial combination with metformin or as add-on 
to   metformin or a glitazone.21,28,33–40 Additional studies also 
showed that there is no serious drug–drug interaction with 
other   common   medications often taken by type 2 diabetic 
patients, eg,   antacids,   anticoagulants and   digitoxin.29–32 A small 
study   investigating the   pharmacokinetics of   saxagliptin in 
patients with hepatic impairment   demonstrated a slower 
  metabolization of   saxagliptin, but no severe side effects.41 
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Figure 2 Pooled data of the HbA1c reductions observed in the clinical studies with saxagliptin (SAXA):34–36,38–40,45 The left hand side of the figure shows the pooled monotherapy 
results, the right side shows the HbA1c reductions in various combinations with either metformin (MET), thiazolidinedione (TZD) or sulfonylurea (SU). In each study, the results 
for doses with 2.5 mg saxagliptin od (light bars) or 5 mg saxagliptin od (dark bars) are shown.
Table 2 Add on combination therapy studies with saxagliptin
SAXA + MET  PBO + MET SAXA + TZD PBO + TZD SAXA + GLY PBO + GLY
Dose 2.5 5 10 – 2.5 5 – 2.5 5 –
n = 186 186 180 175 192 183 180 246 250 264
Basal mean HbAIC   (%) 8.08 8.07 7.98 8.06 8.25 8.35 8.19 8.36 8.48 8.44
Notes: For HbAIC changes, see Figure 2  
Abbreviation: SAXA, saxagliptin; MET, metformin; TZD, thiazolidinedione; PBO, placebo; GLY, glyburide.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 123
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A larger study on the efficacy and safety of   saxagliptin in type 
2 diabetes patients with renal impairment is still ongoing.21
In a head-to-head study comparing sitagliptin as the first 
in class DPP-4 inhibitor with saxagliptin, saxagliptin was 
  noninferior to sitagliptin (press release by AstraZeneca and 
Bristol-Myers Squibb, Oct 5th, 2009). A meta-analysis of 
the existing phase 2 and phase 3 studies showed favorable 
cardiovascular outcomes in the saxagliptin-treated patients.43 
(see Figure 3). The development of saxagliptin as well as the 
other DPP-4 inhibitors emphasizes the advantages of DPP-4 
inhibitors over classical insulin secretagogues (sulfonylureas 
and meglitinides) concerning their glucose-dependent action 
without intrinsic hypoglycemia risk and weight neutrality.44
Saxagliptin has the advantage of having a very high 
selectivity towards DPP-4 and in comparison to sitagliptin 
and vildaglitpin it has a significantly higher potency to inhibit 
DPP-4 in vitro. These effects result in the low dose of the 
drug that has to be administered in type 2 diabetes therapy. 
Whether these in vitro data and the advantage of the low 
drug dose translate into a clinically   meaningful   difference 
to distinguish saxagliptin from the other DPP-4 inhibitors is 
not known yet. The head-to-head study   comparing sitagliptin 
and saxagliptin has shown   noninferiority for saxagliptin. The 
cardiovascular event rates from the combined study program 
carried out for the approval of saxagliptin are very favorable 
and have so far not been shown for the other DPP-4 inhibitors. 
In the long run, however, long-term efficacy and safety data 
are necessary to show the potential advantages of saxagliptin 
in comparison to other DPP-4 inhibitors.
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